Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wataru Okamoto

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Ebiomedicine|July 3, 2015
Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter StudyTakayuki Yoshino, Kei Muro, Kensei Yamaguchi, et al.
ACS Applied Bio Materials|July 28, 2023
Poly(2-ethyl-2-oxazoline)-Conjugated Hemoglobins as a Red Blood Cell SubstituteWataru Okamoto, Yuuki Hiwatashi, Tatsuhiro Kobayashi, et al.
Molecular Cancer Therapeutics|August 19, 2010
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutationWataru Okamoto, Isamu Okamoto, Kaoru Tanaka, et al.
Molecular Cancer Therapeutics|April 22, 2010
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibitionWataru Okamoto, Isamu Okamoto, Takeshi Yoshida, et al.
Clinical Colorectal Cancer|November 14, 2022
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world DataYasutoshi Sakamoto, Hideaki Bando, Yoshiaki Nakamura, et al.
Pathology International|October 8, 2020
Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREENTakeshi Kuwata, Masashi Wakabayashi, Yutaka Hatanaka, et al.
Pathology International|October 6, 2021
The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicineYutaka Hatanaka, Takeshi Kuwata, Eiichi Morii, et al.
Neoplasia (New York, N.Y.)|November 10, 2018
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B StudyHiroya Taniguchi, Wataru Okamoto, Kei Muro, et al.
Investigational New Drugs|August 12, 2015
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumorsAkiyoshi Kasuga, Kazuhiko Nakagawa, Fumio Nagashima, et al.
JCO Precision Oncology|January 20, 2022
International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i>-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing PanelSatoshi Fujii, Anthony M Magliocco, Jihun Kim, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Ebiomedicine|July 3, 2015
Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter StudyTakayuki Yoshino, Kei Muro, Kensei Yamaguchi, et al.
ACS Applied Bio Materials|July 28, 2023
Poly(2-ethyl-2-oxazoline)-Conjugated Hemoglobins as a Red Blood Cell SubstituteWataru Okamoto, Yuuki Hiwatashi, Tatsuhiro Kobayashi, et al.
Molecular Cancer Therapeutics|August 19, 2010
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutationWataru Okamoto, Isamu Okamoto, Kaoru Tanaka, et al.
Molecular Cancer Therapeutics|April 22, 2010
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibitionWataru Okamoto, Isamu Okamoto, Takeshi Yoshida, et al.
Clinical Colorectal Cancer|November 14, 2022
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world DataYasutoshi Sakamoto, Hideaki Bando, Yoshiaki Nakamura, et al.
Pathology International|October 8, 2020
Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREENTakeshi Kuwata, Masashi Wakabayashi, Yutaka Hatanaka, et al.
Pathology International|October 6, 2021
The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicineYutaka Hatanaka, Takeshi Kuwata, Eiichi Morii, et al.
Neoplasia (New York, N.Y.)|November 10, 2018
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B StudyHiroya Taniguchi, Wataru Okamoto, Kei Muro, et al.
Investigational New Drugs|August 12, 2015
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumorsAkiyoshi Kasuga, Kazuhiko Nakagawa, Fumio Nagashima, et al.
JCO Precision Oncology|January 20, 2022
International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i>-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing PanelSatoshi Fujii, Anthony M Magliocco, Jihun Kim, et al.
Pageof 10